Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?

Medical oncology (Northwood, London, England) - 1 Mar 2013

Kim Seung Tae, Sung Jae Sook, Jo Uk Hyun, Park Kyong Hwa, Shin Sang Won, Kim Yeul Hong

Abstract excerpt

The status of epidermal growth factor receptor (EGFR) and Kirsten ras (KRAS) mutations has been used widely in management of patients with non-small cell lung cancer (NSCLC). However, it may be difficult to get tumor tissues for analyzing the status of EGFR and KRAS mutation in large proportion of patients with advanced disease. We obtained pairs of tumor and serum samples from 57 patients with advanced NSCLC,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genes, erbB-1

Share to Kaplan-Meier Estimate

Share to Proportional Hazards Models

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 23307237
DOI: 10.1007/s12032-012-0328-3

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?PMID 23307237Read ↗

Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer?Semantic proximity Read ↗

The clinical relevance of KRAS gene mutation in non-small-cell lung cancer.Semantic proximity Read ↗

KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patientsSemantic proximity Read ↗

[Impact of KRAS in standard treatment of non-small cell lung cancer (NSCLC) patients in 2009: prognostic and predictive value].Semantic proximity Read ↗

KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis.Semantic proximity Read ↗

Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.Semantic proximity Read ↗

[Clinical Analysis of 107 NSCLC Patients Harboring KRAS Mutation].Semantic proximity Read ↗

KRAS mutations in lung cancer.Semantic proximity Read ↗

Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Potential Clinical Significance of a Plasma-Based <i>KRAS</i> Mutation Analysis in Patients with Advanced Non–Small Cell Lung CancerSemantic proximity Read ↗

Can Serum be Used for Analyzing the KRAS Mutation Status in Patients with Advanced Colorectal Cancer?Semantic proximity Read ↗

The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.